Disease behavior in adult patients: Are there predictors for stricture or fistula formation?

Digestive Diseases

Volumn 27, Issue 3, 2009, Pages 206-211

  Dotan, Iris ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Glycans; Prognosis; Serologic markers

Indexed keywords

ANTIBODY; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHITOBIOSIDE CARBOHYDRATE ANTIBODY; FLAGELLIN; FUNGUS ANTIBODY; GLYCAN ANTIBODY; I2 ANTIBODY; LAMINARIBIOSIDE CARBOHYDRATE ANTIBODY; MANNOBIOSIDE CARBOHYDRATE ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN C; SACCHAROMYCES CEREVISIAE ANTIBODY; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

CONFERENCE PAPER; CROHN DISEASE; DIGESTIVE SYSTEM FISTULA; DISEASE CLASSIFICATION; DISEASE COURSE; ENTERITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STRICTURE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PATIENT ATTITUDE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEROLOGY;

ANTIBODIES; BIOLOGICAL MARKERS; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; DISEASE PROGRESSION; FISTULA; GENETIC MARKERS; HUMANS;

EID: 70349924123     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228551     Document Type: Conference Paper

References (37)

1. Barrett JC, Hansoul S, Nicolae DL, et al: Genome- wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-962.
2. Gasche C, Scholmerich J, Brynskov J, et al: A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8-15.
3. Silverberg MS, Satsangi J, Ahmad T, et al: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 9(suppl A):5-36.
4. Cosnes J, Cattan S, Blain A, et al: Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250. (Pubitemid 34784976)
5. Wolters FL, Russel MG, Sijbrandij J, et al: Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006; 55: 1124-1130. (Pubitemid 44085679)
6. Louis E, Collard A, Oger AF, et al: Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-782. (Pubitemid 33096034)
7. Odes S, Vardi H, Friger M, et al: Effect of phenotype on health care costs in Crohn's disease: a European study using the Montreal classification. J Crohn Colitis 2007; 1: 87-96. (Pubitemid 350278497)
8. Loly C, Belaiche J, Louis E: Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43: 948-954.
9. Gupta N, Cohen SA, Bostrom AG, et al: Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology 2006; 130: 1069-1077.
10. Veloso FT, Ferreira JT, Barros L, et al: Clinical outcome of Crohn's disease: analysis according to the Vienna classification and clinical activity. Inflamm Bowel Dis 2001; 7: 306-313. (Pubitemid 33069342)
11. Romberg-Camps MJL, Dagnelie PC, Kester AD, et al: Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009; 104: 371-383.
12. Baert F, Caprilli R, Angelucci E: Medical therapy for Crohn's disease: top-down or step-up? Dig Dis 2007; 25: 260-266.
13. Lichtenstein GR, Yan S, Bala M, et al: Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-869. (Pubitemid 40523539)
14. Ardizonne S, Macconi G, Sampietro GM, et al: Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004; 127: 730-740. (Pubitemid 39208406)
15. Beaugerie L, Seksik P, Nion-Larmurier I, et al: Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-656.
16. Allez M, Lemann M, Bonnet J, et al: Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002; 97: 947-953. (Pubitemid 34408253)
17. Froslie KF, Jahnsen J, Moum BA, et al: Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422. (Pubitemid 47187355)
18. Dotan I, Fishman S, Dgani Y, et al: Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 2006; 131: 366-378. (Pubitemid 44142445)
19. Ferrante M, Henckaerts L, Joosens M, et al: New serological markers in inflammatory bowel disease are associated with complicated disease behavior. Gut 2007; 56: 1394-1403. (Pubitemid 47517833)
20. Dubinsky MC, Lin YC, Dutridge D, et al: Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 2006; 101: 360-367. (Pubitemid 43381681)
21. Forcione DG, Rosen MJ, Kisiel JB, et al: Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004; 53: 1117-1122.
22. Desir B, Amre DK, Lu SE, et al: Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 139-146. (Pubitemid 38180468)
23. Henckaerts L, Pierik M, Josens M, et al: Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 2007; 56: 1536-1542. (Pubitemid 350033192)
24. Dassopoulos T, Frangakis C, Cruz-Correa M, et al: Antibodies to Saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis 2007; 13: 143-151.
25. Papp M, Altorjay I, Dotan N, et al: New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 2008; 103: 665-681.
26. Abreu MT, Tayloe KD, Lin YC, et al: Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123: 679-688. (Pubitemid 34977073)
27. Ippoliti AF, Devlin S, Yang H, et al: The relationship between abnormal innate and adaptive immune function and fibrostenosis in Crohn's disease patients Gastroenterology 2006; 130:A127.
28. Cucchiara S, Latiano A, Palmieri O, et al: Role of CARD15, DLG5 and OCTN genes polymorphisms in children with inflammatory bowel diseases. World J Gastroenterol 2007; 13: 1221-1229. (Pubitemid 46592964)
29. Weersma RK, Stokkers PC, van Bodegraven AA, et al: Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut 2009; 58: 388-395.
30. Rump JA, Scholmerich J, Gross V, et al: A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology 1990; 181: 406-413.
31. Duerr RH, Targan SR, Landers CJ, et al: Anti-neutrophil cytoplasmic antibodies in ulcerative colitis: comparison with other colitides/diarrheal illnesses. Gastroenterology 1991; 100: 1590-1596.
32. Sendid B, Colombel JF, Jacquinot PM, et al: Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol 1996;3: 219-226. (Pubitemid 26104780)
33. Vermeire S, Joosens S, Peeters M, et al: Comparative study of ASCA (anti- Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001; 120: 827-833.
34. Cohavy O, Harth G, Horwiz M, et al: Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infect Immun 1999;67:6510-6517.
35. Landers CJ, Cohavy O, Misra R, et al: Selected loss of tolerance evidenced by Crohn's disease- associated immune responses to autoand microbial antigens. Gastroenterology 2002; 123: 689-699. (Pubitemid 34977074)
36. Lodes MJ, Cong Y, Elson CO, et al: Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004; 113: 1296-1306. (Pubitemid 39069929)
37. Amre DK, Lu SE, Costea F, et al: Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol 2006; 101: 645-652. (Pubitemid 43340944)